Handelsbanken Fonder AB Boosts Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Handelsbanken Fonder AB grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 24.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 63,049 shares of the biopharmaceutical company’s stock after purchasing an additional 12,547 shares during the period. Handelsbanken Fonder AB’s holdings in Regeneron Pharmaceuticals were worth $35,451,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Salomon & Ludwin LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Regeneron Pharmaceuticals in the second quarter valued at $31,000. Traub Capital Management LLC acquired a new stake in Regeneron Pharmaceuticals during the second quarter worth about $38,000. Berbice Capital Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 300.0% during the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 60 shares during the period. Finally, E Fund Management Hong Kong Co. Ltd. increased its holdings in Regeneron Pharmaceuticals by 87.5% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 35 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Up 1.4%

Shares of REGN opened at $781.67 on Friday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. The stock has a fifty day simple moving average of $771.59 and a two-hundred day simple moving average of $680.78. The company has a market capitalization of $82.64 billion, a PE ratio of 18.81, a price-to-earnings-growth ratio of 2.07 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same period last year, the business earned $12.07 earnings per share. Regeneron Pharmaceuticals’s revenue was up 2.5% compared to the same quarter last year. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 5th. Stockholders of record on Friday, February 20th will be given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, February 20th. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.05%.

Analyst Ratings Changes

A number of analysts have recently commented on REGN shares. UBS Group boosted their price objective on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Zacks Research downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. Oppenheimer reaffirmed an “outperform” rating and issued a $865.00 price target (up from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, February 2nd. Bank of America upgraded Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and boosted their price target for the stock from $627.00 to $860.00 in a research report on Wednesday, January 7th. Finally, HSBC upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 24th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $793.81.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Hedge funds and investment sites are highlighting REGN as a top gene-therapy / biotech buy, noting the company’s late-stage pipeline and recent regulatory wins (including a Feb. 24 FDA action referenced in the coverage). Why Regeneron Pharmaceuticals (REGN) is One of the Top Gene Therapy Stocks to Buy According to Hedge Funds
• Positive Sentiment: Regulatory news: the EMA has recommended Dupixent for EU approval to treat chronic spontaneous urticaria (CSU) in children aged 2–11 — if approved this would be a first-in-class targeted option for that age group and should expand addressable market for Dupixent in Europe. Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment
• Positive Sentiment: Analyst momentum: Wall Street Zen (via media coverage) upgraded REGN to a Buy, reflecting bullish analyst sentiment that can support further upside and investor confidence. Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Buy at Wall Street Zen
• Positive Sentiment: Product strength: coverage (Seeking Alpha) emphasizes that Dupixent continues to drive strong sales growth (reported ~22.8% YoY in Q4) and remains central to Regeneron’s long-term revenue outlook. Why Dupixent Keeps Regeneron A Top Big Pharma Pick
• Neutral Sentiment: Relative performance: a recent note asks whether REGN has underperformed the Nasdaq over the past year — a reminder that, despite bullish fundamentals, the stock has lagged broad-market gains and could face rotation risk. Analysts remain largely positive, however. Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.53, for a total value of $77,853.00. Following the sale, the director owned 17,803 shares in the company, valued at $13,860,169.59. The trade was a 0.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jason Pitofsky sold 2,036 shares of the company’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the completion of the transaction, the senior vice president directly owned 4,272 shares in the company, valued at approximately $3,325,837.44. This trade represents a 32.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 5,274 shares of company stock valued at $4,142,738. Insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.